(For faster updates on individual market-movers, Eikon users please use search string "STXBZ US"; for the Day Ahead newsletter, link.reuters.com/mex49s; for the Morning News Call newsletter, link.reuters.com/nex49s) U.S. stock index futures were higher on Friday after strong quarterly results from Alphabet, Microsoft and Amazon fueled a broad rally across the technology sector. Dow Jones industrial average futures were up 0.86 percent at 17,557, S&P 500 futures were up 0.77 percent at 2,068.75 and Nasdaq 100 futures were up 1.35 percent at 4,614.
** ALPHABET INC, Thursday close $681.14, +10.37 pct premarket
** FACEBOOK INC, Thursday close $99.67, +3.18 pct premarket
New revenue streams such as mobile and video advertising should continue to propel earnings of Google parent Alphabet, whose shares were set to open at a record high on Friday following better-than-expected results, analysts said.
Facebook’s shares also rose after Alphabet’s strong results.
** MICROSOFT CORP, Thursday close $48.03, +9.60 pct premarket
The company reported better-than-expected third quarter adjusted revenue for the ninth quarter in a row, driven by demand for cloud products.
** AMAZON.COM INC, Thursday close $563.91, +9.95 pct premarket
The e-commerce company on Thursday recorded a surprise profit for the second quarter in a row, propelled by higher sales in North America and its cloud computing business.
** PANDORA MEDIA INC, Thursday close $19.19, -32.26 pct premarket
The provider of music streaming services reported a bigger quarterly loss as content acquisition costs nearly doubled.
** SPECTRUM PHARMACEUTICALS INC, Thursday close $6.64, -33.43 pct premarket
The biotechnology company said the U.S. FDA declined to approve its Evomela injection to treat patients with multiple myeloma, a form of blood cancer that arises from plasma cells found in bone marrow.
** SKECHERS USA INC, Thursday close $46.19, -27.02 pct premarket
The sports footwear maker and retailer’s revenue missed analysts’ estimates as a strong dollar reduced the value of international sales.
** MERRIMACK PHARMACEUTICAL INC, Thursday close $8.71, +10.56 pct premarket
The U.S. Food and Drug Administration on Thursday approved the company’s pancreatic cancer drug, Onivyde, with a severe safety warning.
** PROCTER & GAMBLE CO, Thursday close $74.85, -1.15 pct premarket
The company reported its biggest drop in quarterly sales in seven quarters, hurt by weak demand across product categories and a strong dollar.
** TESLA MOTORS INC, Thursday close $211.72, +1.97 pct premarket
The company could begin producing cars in China in two years, Chief Executive Elon Musk said, adding that local production had the potential to cut the sales prices of its models in the world’s largest auto market by a third.
** TREEHOUSE FOODS INC, Thursday close $84.22
** CONAGRA FOODS INC, Thursday close $42.39
TreeHouse is in advanced talks to acquire Ralcorp, the private label business of ConAgra Foods, in a deal that could be valued between $2.5 billion and $2.7 billion, according to people familiar with the matter.
** AT&T INC, Thursday close $33.96, +2.18 pct premarket
The No. 2 U.S. wireless carrier and the world’s largest pay-TV operator raised its 2015 earnings forecast as quarterly earnings beat expectations on cost cuts and gains in wireless and DirecTV subscribers.
** WHIRLPOOL CORP, Thursday close $159.81, +5.75 pct premarket
The world’s largest maker of home appliances posted a higher quarterly net profit on Friday as benefits from costs and capacity reductions, acquisitions, and favorable price-mix offset declining demand in Latin America and unfavorable currency exchange rates.
** AMERICAN AIRLINES GROUP INC, Thursday close $45.99, +3.28 pct premarket
The world’s largest airline on Friday reported a third-quarter profit above analysts’ expectations, as cheap fuel continued to help its bottom line.
** YUM BRANDS INC, Thursday close $72.68, +0.78 pct premarket
As the parent of KFC, Pizza Hut and Taco Bell looks to triple its store footprint in China and revive flagging growth there, it faces a hurdle with one of its traditional growth drivers: the country’s underdeveloped franchise market.
** HALLIBURTON CO, Thursday close $39.71, +0.98 pct premarket
** BAKER HUGHES INC, Thursday close $55.59
Australia’s antitrust regulator raised concerns on Friday about Halliburton’s proposed $35 billion buyout of rival Baker Hughes, in another setback for a deal that has already hit competition snarls in the United States.
** GNC HOLDING INC, Thursday close $34.5, +1.42 pct premarket
The nutritional products retailer sold dietary supplements containing two illegal synthetic drugs in the United States, Oregon’s attorney general alleged in a lawsuit.
** UNITED CONTINENTAL HOLDINGS INC, Thursday close $56.05, +2.14 pct premarket
United Airlines on Thursday tried to dismiss concerns that executive shake-ups have left an amateur team running its business, promising better service for travelers and moderate expansion in 2016 for investors worried about weak demand.
** GENERAL MOTORS CO, Thursday close $35.42, +0.93 pct premarket
The United Auto Workers said on Thursday it will negotiate its next deal with General Motors, after the union’s workers at Fiat Chrysler Automobiles NV ratified a new pact.
** THOMSON REUTERS CORP, Thursday close $42.25
The company on Friday reported a higher-than-expected quarterly profit even as revenue dipped, hurt by foreign currency, and the news and information company reaffirmed its full-year forecast.
** ABBVIE INC, Thursday close $48.27, +0.99 pct premarket
U.S. health regulators on Thursday issued a warning of potential risk of serious liver injury for certain patients using the company’s hepatitis C treatments, Viekira Pak and Technivie.
** AUTOLIV INC, Thursday close $116.98, +3.31 pct premarket
The auto safety gear maker reported third quarter core earnings that narrowly beat market expectations on Friday and said it expected like-for-like sales to grow around 7 percent this year.
** AMGEN INC, Thursday close $152.31, +1.31 pct premarket
An experimental Amgen drug based on a tumour-killing virus was given a green light by European regulators on Friday, paving the way for the novel treatment’s approval within a couple of months. (Compiled by Manish Parashar in Bengaluru; Editing by Maju Samuel)